EUVIMEDEUVIMED entdecken
Crossref

Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors

Wajd Alkabbani iD, John-Michael Gamble iD

British Journal of Clinical Pharmacology · 2023-02 · 89 (2) · 431-439

DOI: 10.1111/bcp.15178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 03.02.2022. Verfasst von Wajd Alkabbani und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Waterloo, Kitchener, ON, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Diabetic Ketoacidosis, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Disproportionality analysis is a common pharmacovigilance tool to detect safety signals of type 2 diabetes medications from spontaneous drug reporting databases. The aim was to demonstrate the impact of using active‐comparator restricted disproportionality analysis (ACR‐DA), wherein the reference group is restricted to reports with a clinically appropriate active comparator.

Methods

Using reports from the Food and Drug Administration Adverse Event Reporting System, we assessed if sodium/glucose cotransporter 2 (SGLT2) inhibitors are associated with higher reporting of 5 potential adverse events: acute kidney injury, genitourinary tract infections, diabetic ketoacidosis, fractures, and amputations. For each adverse event, we calculated the proportional reporting ratio (PRR) and adjusted reporting odds ratio (aROR [95% confidence interval, CI]) using 3 types of reference groups: no SGLT2 inhibitor (background risk reference), other diabetes drugs (therapeutic class reference), and dipeptidyl peptidase 4 inhibitors (active comparator reference).

Results

Based on ACR‐DA, we did not detect a safety signal for acute kidney injury (PRR 0.92 [0.81–1.04]; aROR 0.78 [95% CI 0.72–0.85]) or fractures (PRR 0.44[95% CI 0.17–1.15]; aROR 0.74 [95% CI 0.61–0.91]) associated with SGLT2 inhibitors compared to dipeptidyl peptidase 4 inhibitors. However, we detected safety signals for genitourinary tract infections (PRR 2.75[2.02–3.76]; aROR 2.54[2.26–2.86], diabetic ketoacidosis (PRR 63.85[39.37–103.53; aROR 91.49[70.66–118.48]), and amputations (PRR 52.60 [19.66–140.75]; aROR 22.64 [15.32–33.42].

Conclusion

The use of the proposed ACR‐DA to detect safety signals of type 2 diabetes medications may reduce false positive safety signals through careful selection of the comparator which is expected to reduce channelling bias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDiabetic KetoacidosisSodium-Glucose Transporter 2 InhibitorsAcute Kidney InjuryHumansPharmacovigilanceAdverse Drug Reaction Reporting SystemsChronic DiseaseGlucoseSodium

Stichwörter der Autor:innen

active comparator, disproportionality analysis, pharmacovigilance, restriction,…

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsGlucoseSodium

Autor:innen und Institutionen

  • School of Pharmacy, University of Waterloo, Kitchener, ON, Canada.

ORCID-Profile: Wajd Alkabbani, John-Michael Gamble

Zitieren

APA

Alkabbani, W., & Gamble, J. M. (2023). Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors. British Journal of Clinical Pharmacology, 89(2), 431-439. https://doi.org/10.1111/bcp.15178

Vancouver

Alkabbani W, Gamble JM. Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors. British Journal of Clinical Pharmacology. 2023;89(2):431-439. doi:10.1111/bcp.15178

BibTeX
@article{Alkabbani2023,
  author = {Alkabbani, Wajd and Gamble, John-Michael},
  title = {Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {2},
  pages = {431--439},
  doi = {10.1111/bcp.15178}
}
Kostenlos starten →